CClinicalTrials.gg
RecruitingNCT05935696TUS-TBEUpdated Jul 7, 2023

A Prospective Observational Study on the Role of Transthoracic Ultrasound in Differentiating Tuberculous From Malignant Pleural Effusion

An observational study in Pleural Effusion, Tuberculosis, Pleural and Malignant Pleural Effusion, sponsored by Sarawak General Hospital. Recruiting at 1 site in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-07.

Sponsored by Sarawak General Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Primary Endpoint

  • To assess the prevalence and diagnostic performance of pre-determined echographic features in predicting the diagnosis of TBE from MPE.
  • To determine the clinical, pleural fluid and echographic parameters that were different among TBE and MPE and to establish a clinical prediction model for TBE.

Secondary Endpoint

  • To assess the correlation between pleural fluid parameters with ultrasound and medical thoracoscopic finding.
  • To assess the optimal Pf ADA cut-off value to differentiate TBE from MPE in our region.
Read the detailed description

Tuberculous (TBE) and malignant pleural effusion (MPE) is the commonest cause of exudative pleural effusion in Malaysia. Early differentiation between these two diagnoses is essential as TBE only requires drainage if symptomatic, whereas MPE would require tissue biopsy for diagnosis confirmation and molecular profiling. However, both TBE and MPE present almost similarly with lymphocytic exudates. Pleural fluid (Pf) indices such as adenosine deaminase (ADA) may allow differentiation between these two entities in appropriate clinical circumstances. However, Pf ADA may not readily be accessible in resource-limited regions and the optimal cut-off varies depending on the local prevalence of tuberculosis. As a result, TBE diagnosis in our region is still heavily dependent on the analysis of pre-existing clinical demographic data and Pf parameters, where ultimately requiring pleural biopsy for a confident clinical diagnosis.

Point-of-care predictors for TBE, such as ultrasound imaging appearance, may be helpful, but have rarely been described. Previous studies have demonstrated that a complex septated ultrasound pattern in lymphocytic pleural effusion is a potentially useful diagnostic predictor to differentiate TBE from MPE with a positive predictive value of 94% and likelihood ratio of 12.2 TBE diagnostic algorithms frequently include only clinical indices with Pf parameters such as Pf differential cell count, ADA, protein and lactate dehydrogenase (LDH). Incorporation of point-of-care ultrasound finding into the clinical diagnostic algorithm has not been extensively explored.

TBE is the result of a delayed type IV hypersensitivity reaction to mycobacterial protein; fibrin formation in the pleural cavity is largely driven by pro-inflammatory cytokines as well as a reduction of fibrinolytic activity due to pleural inflammation. In contrast, MPE is believed to be driven by a high degree of anaerobic metabolism leading to lactic acid production, rather than an inflammatory response. These different pathogenic mechanisms in TBE and MPE resulted in different pleural fluid parameters such as lower Pf glucose and pH with higher Pf LDH level in MPE when compared to TBE. We believed that this principle may be extrapolated to discriminative ultrasound findings between TBE and MPE.

The result from our retrospective pilot study found that the presence of echographic septation had an adjusted odds ratio of 9.28 in prediction of TBE diagnosis from MPE. Along with other clinical parameters (male gender, serum leucocyte counts 9 x 109/L or, pleural fluid protein 50g/L or more), these parameters collectively report a diagnostic accuracy of 79.61% (95% CI 74.13-84.38) for TBE. In a previous study conducted in region with low tuberculosis burden, pleural thickening of >1cm, pleural nodularity and diaphragmatic thickening of >7mm on transthoracic ultrasound were highly suggestive of MPE. However, not uncommonly, we observed similar pattern of pleural and diaphragmatic thickening in TBE patients in our region as well.

As TBE is a hypersensitivity process with significant inflammatory response, we hypothesize that echographic septation, in addition to pleural thickening and other sonographic findings, may be a good indicator, as part of a clinical prediction model to discriminate TBE from MPE in our region.

02

Conditions studied

  • Pleural Effusion
  • Tuberculosis, Pleural
  • Malignant Pleural Effusion

Keywords

  • pleural effusion
  • transthoracic ultrasound
  • tuberculous pleural effusion
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All adult patients more than 18 years old who presented with undiagnosed pleural effusion scheduled for diagnostic medical thoracoscopy in all respective sites during first quarter of 2023 for six months will be considered for inclusion.

Inclusion criteria

  • All adult patients 18 years old or more
  • Undiagnosed exudative pleural effusion planning for diagnostic medical thoracoscopy

Exclusion criteria

Exclusion Criteria:

  • Patient less than 18 years old
  • Patient for therapeutic medical thoracoscope (i.e., medical thoracoscopic adhesiolysis in patient with parapneumonic pleural effusion) in which diagnosis is already known.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Tuberculous Pleural Effusion

    Tuberculous pleural effusion (TBE) if any of the following criteria is presence: * Histological evidence of caseating granuloma from pleural biopsy * Microbiological evidence (positive growth of Mycobacterium tuberculosis culture, positive TB-PCR, positive Xpert MTB/RIF) from pleural fluid or pleural biopsy specimen * In patients with positive sputum smear for acid fast bacilli, sputum positive for mycobacterium tuberculosis culture, sputum positive for Xpert MTB/RIF or TB-PCR with no apparent cause of an exudative pleural effusion Patient without histological or microbiological evidence who demonstrated therapeutic response to anti-tuberculosis drugs will not be accepted as TBE in current study.

  • Malignant Pleural Effusion (Control)

    Malignant pleural effusion (MPE) if any of the following criteria is presence: • Histological or cytological evidence of specific histopathological diagnosis of malignancy from pleural biopsy Patient without histological or cytological evidence or malignancy (para-malignant) will not be considered as MPE in the context of this study.

05

What researchers measure

Primary outcomes

  1. Transthoracic ultrasound

    To assess the prevalence and diagnostic performance of pre-determined echographic features in predicting the diagnosis of TBE from MPE.

    Time frame: 12 months

06

Study locations

1 of 1 sites recruiting
  • Sarawak General Hospital
    Kuching, Sarawak 93586, Malaysia
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05935696
Lead sponsor
Sarawak General Hospital
Collaborators
Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Institute of Respiratory Medicine Malaysia, Kuala Lumpur, Hospital Serdang, Selangor, University Malaya Medical Center, Selangor, Hospital Melaka, Melaka
Responsible party
Kho Sze Shyang (Dr., Sarawak General Hospital) — Principal investigator
First posted
Jul 7, 2023
Start date
Apr 1, 2023
Primary completion
Mar 31, 2024 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Jul 7, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion